Tuesday, July 15, 2025
LBNN
  • Business
  • Markets
  • Politics
  • Crypto
  • Finance
  • Energy
  • Technology
  • Taxes
  • Creator Economy
  • Wealth Management
  • Documentaries
No Result
View All Result
LBNN

Sage Hints at Difficult Decisions After Zuranolone’s Rejection in MDD

Simon Osuji by Simon Osuji
August 7, 2023
in Technology
0
FDA’s Second Rejection Ends Intercept’s NASH Aspirations
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

FDA_Grandbrothers/Adobe Stock

An FDA sign on a lawn with Autumn leaves/Adobe Stock, Grandbrothers

Shares of Sage Therapeutics were down 46% in premarket trading Monday following the receipt of an FDA Complete Response Letter for its application for zuranolone in major depressive disorder on Friday.

Zurzuvae (zuranolone)—being developed with partner Biogen for both major depressive disorder (MDD) and postpartum depression (PPD)—was approved Friday as the first oral medication for PPD. On a conference call Monday, Sage executives struck a celebratory note, with CEO Barry Greene calling the approval “a historic moment for all women suffering from PPD.”

But MDD was clearly the prize for Sage and Biogen. PPD affects approximately half a million women in the U.S. each year, Greene said, while an estimated 21 million adults had at least one major depressive episode in 2021, according to a survey conducted by the National Institute of Mental Health.

Mike Yee, a biotech analyst at Jefferies, told Reuters that the drug’s “use as a clinical depression treatment represents a more than $1 billion sales opportunity compared with $250 million to $500 million potential for postpartum depression.”

Thus, despite reassurances in its second quarter business update issued Monday that the company believes itself to be “well capitalized,” Greene said Sage is “currently evaluating resource allocation, including pipeline prioritization and a workforce reorganization,” with the goal of extending its cash runway. Sage anticipates operating expenses will decrease in 2024, according to the press release.

Biogen Also Takes a Hit

While Biogen fared much better on the stock market—the bigger biotech’s shares fell just 3% in premarket trading Monday—Baird analyst Brian Skorney told Reuters the FDA’s decision to not approve zuranolone for a much larger cohort of patients with clinical depression, along with the drug’s “strict safety warnings” in PPD, “is still a strike against Biogen’s management.”

Safety information on the Zurzuvae’s label includes a boxed warning around driving and guidance stating that the drug “can be abused or lead to dependence.”

In its Complete Response Letter, the FDA stated that the NDA in MDD did not provide “substantial evidence of effectiveness” to support its approval and that further research would be required.

In the Phase III CORAL study, zuranolone given with a standard of care antidepressant showed a statistically significant reduction in depressive symptoms after three days of treatment, an effect that was sustained after two weeks. However, in an earlier Phase III study, the drug failed to distinguish itself from placebo.

On Friday, Biogen CEO Chris Viehbacher said the partners would “thoroughly review the feedback from the FDA on the use of zuranolone in MDD to determine next steps.”

Greene declined to elaborate on this statement during Monday’s conference call, saying only that the companies are “reviewing the feedback and evaluating next steps.” 

Yee told Reuters that Biogen is unlikely to “quickly move forward on another late-stage study for MDD,” given its focus on saving costs and recent announcements of job cuts.

In a statement on Friday, Greene expressed his disappointment with the FDA’s decision in MDD, saying the companies were “highly disappointed for patients, particularly amid the current mental health crisis.” He reiterated this sentiment on Monday’s call and added that Sage and Biogen “learned late in the review cycle the FDA’s view on approvability of zuranolone in MDD,” a view he said Sage does not agree with.

Heather McKenzie is a senior editor at BioSpace. You can reach her at heather.mckenzie@biospace.com. Follow her on LinkedIn and Twitter @chicat08.

Related posts

AMCEN 20: Greenpeace urges ministers to deliver bold action on plastics, climate justice, forest protection – EnviroNews

AMCEN 20: Greenpeace urges ministers to deliver bold action on plastics, climate justice, forest protection – EnviroNews

July 15, 2025
NYSC dream to nutrition enterprise: How BATN Foundation’s F4F grant transformed Pemnia Wellness – EnviroNews

NYSC dream to nutrition enterprise: How BATN Foundation’s F4F grant transformed Pemnia Wellness – EnviroNews

July 15, 2025

Source link

Previous Post

The two teams the Kansas City Chiefs could trade Chris Jones to

Next Post

Lil Meech & Summer Walker Trade Post-Breakup Shade

Next Post
Lil Meech & Summer Walker Trade Post-Breakup Shade

Lil Meech & Summer Walker Trade Post-Breakup Shade

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

RECOMMENDED NEWS

Jobberman and four companies form Alliance to tackle youth unemployment in Nigeria

Jobberman and four companies form Alliance to tackle youth unemployment in Nigeria

2 years ago
Lebanon Says Seven Killed in Clashes on Syria Border

Lebanon Says Seven Killed in Clashes on Syria Border

4 months ago
Khamis family loses over $44 million from Oriental Weavers stake

Khamis family loses over $44 million from Oriental Weavers stake

8 months ago
A social app for creatives, Cara grew from 40k to 650k users in a week because artists are fed up with Meta’s AI policies

A social app for creatives, Cara grew from 40k to 650k users in a week because artists are fed up with Meta’s AI policies

1 year ago

POPULAR NEWS

  • Ghana to build three oil refineries, five petrochemical plants in energy sector overhaul

    Ghana to build three oil refineries, five petrochemical plants in energy sector overhaul

    0 shares
    Share 0 Tweet 0
  • When Will SHIB Reach $1? Here’s What ChatGPT Says

    0 shares
    Share 0 Tweet 0
  • The world’s top 10 most valuable car brands in 2025

    0 shares
    Share 0 Tweet 0
  • Top 10 African countries with the highest GDP per capita in 2025

    0 shares
    Share 0 Tweet 0
  • Global ranking of Top 5 smartphone brands in Q3, 2024

    0 shares
    Share 0 Tweet 0
  • Privacy Policy
  • Contact

© 2023 LBNN - All rights reserved.

No Result
View All Result
  • Home
  • Business
  • Politics
  • Markets
  • Crypto
  • Economics
    • Manufacturing
    • Real Estate
    • Infrastructure
  • Finance
  • Energy
  • Creator Economy
  • Wealth Management
  • Taxes
  • Telecoms
  • Military & Defense
  • Careers
  • Technology
  • Artificial Intelligence
  • Investigative journalism
  • Art & Culture
  • Documentaries
  • Quizzes
    • Enneagram quiz
  • Newsletters
    • LBNN Newsletter
    • Divergent Capitalist

© 2023 LBNN - All rights reserved.